The effectiveness of chemotherapy combined with endostatin in treating patients with advanced first-line NSCLC and negative driver genes was initially validated by the ECOG4599 study.[13] Endostar, the first endostatin independently developed in China and introduced in 2006, primarily exerts its anti-tumor effects by downregulating vascular endothelial growth factor and its receptor. This evidence concerns the gene VEGFA and non-small cell lung carcinoma.